January 11, 2026 (InterContinental San Francisco) — We’re pleased to announce that Kai Lin, Ph.D., Chief Scientific Officer at Sunshine Lake Pharma (HEC Pharm), will speak at the ACCESS ASIA BD Forum @ JPM 2026.
ACCESS ASIA, hosted by YAFO, builds on the success of ACCESS CHINA, expanding Asia’s leading cross-border biotech platform to connect innovators with global pharma, investors, and strategic partners. Taking place on January 11, 2026, at the InterContinental San Francisco, the forum provides a global stage for Asian biotech companies to showcase their innovation, foster partnerships, and explore new business development opportunities. View more information at: https://biotochina.org/
About Sunshine Lake Pharma (HEC Pharm)
Sunshine Lake Pharmaceutical Co., Ltd. (also known as HEC Pharm; HKEX: 06887) is a fully integrated pharmaceutical company with a strong focus on infectious diseases, oncology, metabolic, and other chronic diseases. Established in 2005, HEC’s R&D center in Guangdong, China, employs over 1,000 scientists and provides end-to-end drug discovery and development capabilities. HEC’s technology platforms span all major therapeutic modalities, including small molecules, oligonucleotides, peptides, antibodies, antibody–drug conjugates (ADCs), and cell therapies (CAR-T and stem cells). The company has three innovative drugs approved and a robust pipeline of more than 40 candidates at various stages of development, and is actively seeking global partnerships.
About the speaker
Dr. Kai Lin is the Chief Scientific Officer of Sunshine Lake Pharma (HEC Pharm), with over 25 years of experience in drug discovery across liver and metabolic diseases, infectious diseases, and oncology. He has led programs across multiple therapeutic modalities, including small molecules, siRNA, antibodies, and ADCs, and has successfully advanced two dozen INDs and several NDAs. Prior to joining HEC Pharm, Dr. Lin served as Senior Vice President and Head of Research at Aerium Therapeutics in Boston and held progressively leadership roles at Vertex Pharmaceuticals (five years), Novartis (eight years), Enanta Pharmaceuticals (six years), and other biotech companies, including Permeon Biologics, Idenix Pharmaceuticals, and Atea Pharmaceuticals. He earned his B.S. in Biochemistry from Nankai University and Ph.D. in Biochemistry from the University of Pennsylvania, has published more than 50 peer-reviewed articles, and is a co-inventor on over 30 patents.
About ACCESS ASIA BD Forum @ JPM 2026
ACCESS ASIA BD Forum @ JPM is scheduled to be held on January 11, 2026, at the InterContinental San Francisco, alongside the J.P. Morgan Healthcare Conference Week.
This full-day forum will feature keynote speeches, panel discussions, corporate presentations, company showcases, and 1-on-1 partnering meetings connecting Asia’s leading biotech innovators with global pharma, investors, and strategic partners.
Conference Name: ACCESS ASIA BD Forum @ JPM 2026
Date & Venue: January 11, 2026 | InterContinental San Francisco
View more information at: https://biotochina.org/
MORE INFORMATION
Contact Us
Register as an attendee for ACCESS ASIA BD Forum @ JPM:
For more information, please contact:
Wendi Xiang | Wxiang@yafocapital.com
BioToChina.org 